Deciphex, a Dublin, Ireland-based AI-powered digital pathology company, raised €31M in Series C funding.
The round was led by Molten Ventures with participation from ACT Venture Capital, Seroba, Charles River Laboratories (NYSE: CRL), IRRUS Investments, HBAN Medtech Syndicate and Nextsteps Capital.
The company intends to use the funds to:
- scale global service reach.
- enhance utility of its platforms.
- accelerate pathology AI foundational model development.
- strengthen partnerships with industry leaders.
- expand services to Pharma/Biotech and CRO clients.
Led by CEO and Founder Donal O’Shea, Deciphex empowers diagnostic workflows through AI-powered digital pathology to improve patient outcomes worldwide. Its two flagship platforms target distinct markets: Diagnexia connects global subspecialty pathologists for rapid diagnostics and backlog reduction, while Patholytix accelerates drug development through optimized preclinical safety assessments.
By automating routine tasks, these platforms enable pathologists to focus on complex cases while delivering faster, more reliable diagnoses. Through this combination of AI innovation and clinical expertise, Deciphex is advancing both healthcare delivery and therapeutic development.
FinSMEs
07/01/2025